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Abstract
Introduction The hyperplastic enlarged lobular unit (HELU) is a
common alteration in adult female human breast and is the
earliest histologically identifiable lesion with premalignant
potential. Growth and differentiation in normal epithelium are
regulated by estrogen and progesterone, whose effects are
mediated through estrogen receptor (ER)-α and progesterone
receptor (PR). We assessed correlations between growth
(proliferation and apoptosis), endogenous hormone levels
(using age as a surrogate for menopausal/estrogen status), and
ER-α/PR expression in HELUs versus adjacent normal terminal
duct lobular units (TDLUs) to gain insight into potentially
premalignant hyperplasia.
Methods Proliferation (Ki67 antigen), ER-α, and PR were
assessed by immunohistochemistry, apoptosis using the
TUNEL (terminal transferase-mediated dUTP nick end-labeling)
assay, and nuclear colocalization of ER-α and Ki67 by dual-
labeled immunofluorescence in HELUs and adjacent TDLUs (n
= 100–584, depending on the factor) from 324 breasts. All
factors were quantified under direct microscopic visualization.
ER-α/PR expression was semiquantified by estimating the
proportion of positive cells (0 = none, 1 = <1/100, 2 = 1/100
to 1/10, 3 = 1/10 to 1/3, 4 = 1/3 to 2/3, and 5 = >2/3). Ki67,
TUNEL, and colocalization of ER-α and Ki67 were scored by
absolute counting (%positive).
Results ER-α and PR expression were significantly elevated in
HELUs versus adjacent TLDUs (average score: 4.5 versus 3.1
and 3.5 versus 2.1; P  < 0.0001). Proliferation was also
significantly higher in HELUs versus TDLUs (average 6.3%
versus 2.0%; P  < 0.0001). In contrast, apoptosis was
significantly lower in HELUs versus TDLUs (average 0.61%
versus 0.22%; P  < 0.0001). Changes in proliferation and
receptor expression were similar between premenopausal and
postmenopausal TDLUs and HELUs, suggesting that
hyperplastic cells remain responsive to regulation by estrogen.
The proportion of ER-positive/proliferating cells was much
higher in HELUs than TDLUs (27.6% vs. 4.9%; P < .0001).
Conclusion Development of HELUs is associated with
increased proliferation and decreased cell death relative to
normal cells. ER-α and PR are highly elevated in HELUs, which
may contribute to the hyperplasia because they mediate
hormonal regulation of growth. An understanding of the
fundamental causes of increased levels of receptors and growth
may lead to new strategies to prevent breast cancer.
Introduction
Enlarged terminal duct lobular units (TDLUs) are common
alterations in the adult female human breast. They are typically
lined by crowded columnar epithelial cells, and the degree of
enlargement can be substantial (Fig. 1). They have been dis-
cussed intermittently in the medical literature since the early
1900s, if not earlier, and some authors speculated as far back
as then that they may have premalignant potential [1-3]. Con-
sistent with this, a handful of recent studies [4-6] assigned a
weak (about twofold) increased relative risk for developing
breast cancer to enlarged lobules.
ADH = atypical ductal hyperplasia; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HELU = hyperplastic enlarged lobular unit; IBC = inva-
sive breast cancer; PR = progesterone receptor; TDLU = terminal duct lobular unit; TGF = transforming growth factor; TUNEL = terminal transferase-
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Because of the long and somewhat sporadic interest in this
lesion, and because the histologic features of the epithelium
lining the enlarged lobules may vary (e.g. size, shape, and aty-
pia), it has been referred to by many terms over the years,
including abnormal involution [1], columnar distention of acini
[7], blunt duct adenosis [8], atypical lobules type A [9], colum-
nar alteration of lobules [10], and columnar cell lesions with or
without atypia [11] to name but a few. There has been consid-
erable renewed interest in these lesions during the past few
years, primarily because of their possible premalignant poten-
tial, which has resulted in even more diverse terminology as
pathologists have struggled to define subtypes that encom-
pass their histological variability [3,5,11-13].
From another perspective, this alteration can be viewed as a
biological process in which the common unifying features are
cellular hyperplasia resulting in enlargement of lobules. In this
sense, we prefer the more general descriptive terminology
'hyperplastic enlarged lobular units', and the abbreviation
HELU has symmetry with TDLU, from which HELUs evolve.
Staying with a biological viewpoint, the histological diversity of
HELUs can be seen as morphologic manifestations of variable
differentiation and/or acquired genetic alterations in the cells.
Hyperplasia is defined as an increase in cell number that may
result in the enlargement of a tissue [14]. It can be a physio-
logic or pathologic process, and the latter is often associated
with delayed or altered differentiation. Growth and differentia-
tion in normal breast epithelium are regulated by many biolog-
ical mechanisms that include, in particular, the hormones
estrogen and progesterone, whose effects are mediated
through the estrogen receptor (ER)-α and progesterone
receptor (PR), functioning as nuclear transcription factors
[15,16]. In this study we examined correlations between
growth (proliferation and apoptosis), endogenous hormone
levels (using age as a surrogate for menopausal/estrogen sta-
tus), and ER-α/PR expression in HELUs as compared with
adjacent normal TDLUs in order to gain insight into the relative
loss of growth control (i.e. hyperplasia) associated with the
development of HELUs.
Materials and methods
ER-α, PR, Ki67, apoptosis, and ER-α/Ki67 colocalization were
assessed in formalin-fixed paraffin-embedded tissue samples
of adult female human breast tissue from the Baylor College of
Medicine affiliated hospitals, with institutional review board
approval. The study population consisted of 324 total breasts
and each biomarker was evaluated in large overlapping
subsets of this population (because of their small size, not all
TDLUs and HELUs could be evaluated for all factors).
ER-α was evaluated by immunohistochemistry in 615 TDLUs
and 398 HELUs from 262 breasts, including 238 breasts con-
taining at least one TDLU and one adjacent HELU. The immu-
nohistochemical assay used mouse monoclonal antibody
6F11 (Novocastra, Newcastle, UK) specific for ER-α and a
standard detection system as previously described [17]. ER-α
expression was quantified by estimating the proportion of pos-
itive staining nuclei as previously described (0 = none, 1 = <1/
100, 2 = 1/100 to 1/10, 3 = 1/10 to 1/3, 4 = 1/3 to 2/3, and
5 = >2/3) [17,18].
PR was assessed by immunohistochemistry in 647 TDLUs
and 584 HELUs from 319 breasts, including 269 breasts with
at least one TDLU and one adjacent HELU. The immunohisto-
chemical assay used mouse monoclonal antibody 1294
(Dako, Carpinteria, CA, USA) against PR (A and B isoforms)
[19] and a standard detection system as previously described
[20]. PR expression was quantified in the same manner as ER-
α.
Proliferation rate was assessed in 249 TDLUs and 137
HELUs from 114 breasts, including 81 breasts with at least
one TDLU and one adjacent HELU. The immunohistochemical
assay used mouse monoclonal antibody MiB1 (Dako) against
the Ki67 proliferation-associated protein and a standard
detection system as previously described [21]. The prolifera-
tion rate was quantified by absolute counting of positive and
Figure 1
HELUs are much larger than normal TDLUs HELUs are much larger than normal TDLUs. This photomicrograph 
shows a normal type 1 TDLU adjacent to a typical HELU. In this exam-
ple, the TDLU measures about 0.4 mm in diameter, contains about 150 
cells within this area, and approximately 4000 total cells. The HELU 
measures about 2.0 mm in diameter, contains about 1500 cells within 
this area, and approximately 200,000 total cells (i.e. a 50-fold increase 
relative to the TDLU). Estimates of cell counts were based on calcula-
tions assuming all cells measure 10 µm in thickness and are evenly dis-
tributed within a sphere the diameter of the TDLU or HELU. Typical 
HELUs measure between 1 and 4 mm in diameter, and so the magni-
tude of the hyperplasia may be somewhat smaller or larger than shown 
in this example, depending on the size. HELU, hyperplastic enlarged 
lobular unit; TDLU, terminal duct lobular unit.Available online http://breast-cancer-research.com/content/8/1/R6
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negative cells in each sample (average about 500 cells/sam-
ple) and expressed as percentage positive.
Apoptotic rate was assessed in 433 TDLUs and 396 HELUs
from 165 breasts, including 133 breasts containing at least
one TDLU and one adjacent HELU, using the terminal trans-
ferase-mediated dUTP nick end-labeling (TUNEL) assay as
previously described [22]. Rates were quantified by absolute
counting of positive and negative cells in each sample (aver-
age about 500 cells/sample) and expressed as percentage
positive.
Colocalization of ER-α and Ki67 was assessed by dual-
labeled immunofluorescence in 100 TDLUs and 100 HELUs
from the same 25 breasts. ER-α was labeled with mouse mon-
oclonal antibody 6F11 (Novocastra) and anti-mouse linking
antibody conjugated to red fluorochrome Alexa 594 (Molecu-
lar Probes Inc., Eugene, OR, USA). Ki67 was labeled with rab-
bit polyclonal antibody Ki67 (Novocastra) and anti-rabbit
linking antibody conjugated to green fluorochrome Alexa 488
(Molecular Probes). Colocalization was quantified by absolute
counting of all Ki67 positive cells, which were either positive
or negative for ER-α expression and expressed as percentage
dual-positive cells relative to total Ki67 positive cells.
Comparisons of expression were performed using two-way,
mixed model analysis of variance, with both fixed effects and
random effect to account for the fact that some breasts con-
tained both types of samples (i.e. TDLUs and HELUs) whereas
others contained only one type, respectively. The linear model
from the analysis of variance was used to compute least
squares means and approximate standard errors for each
group. Least square means estimate population means, bal-
ancing for uneven numbers of observations of TDLUs and
HELUs within individual breasts. The term 'average' was used
in place of 'least square means' throughout this manuscript to
improve readability. Comparisons of age groups within sample
types were accomplished with linear contrasts and analyses
were performed with SAS software (version 9.1; SAS Institute
Inc., Cary, NC).
Figure 2
Receptor expression and growth Receptor expression and growth. This figure compares normal TDLUs and HELUs for ER-α expression, PR expression, proliferation (Ki67 antigen), 
apoptosis (TUNEL assay), and colocalization of ER-α and Ki67 in the same cells. aAverage proportion score (± SEM) representing the estimated 
proportion of positive cells (0 = none, 1 < 1/100, 2 = 1/100 to 1/10, 3 = 1/10 to 1/3, 4 = 1/3 to 2/3, and 5 = >2/3). ER, estrogen receptor; HELU, 
hyperplastic enlarged lobular unit; PR, progesterone receptor; SEM, standard error of the mean; TDLU, terminal duct lobular unit; TUNEL, terminal 
transferase-mediated dUTP nick end-labeling.Breast Cancer Research    Vol 8 No 1    Lee et al.
Page 4 of 9
(page number not for citation purposes)
Results
Receptor expression and growth
ER-α expression, PR expression, proliferation rate (Ki67),
apoptosis rate (TUNEL), and the percentage of proliferating/
ER-α-positive cells are shown in Fig. 2. ER-α expression was
significantly higher in HELUs than in TDLUs, with proportion
scores averaging 4.5 ± 0.05 and 3.1 ± 0.05, respectively (P
< 0.0001). These values roughly correspond to about 85%
and 35% average positive cells, but the scores are nonlinear
estimates of proportion and difficult to convert to exact per-
centages. Similarly, PR expression was significantly higher in
HELUs than in TDLUs, with proportion scores averaging 3.5 ±
0.08 and 2.1 ± 0.08 (P < 0.0001), respectively, correspond-
ing to roughly 50% and 15% positive cells. ER-α and PR
expression were significantly higher in HELUs than in adjacent
TDLUs in 85% of breasts containing both types of samples,
whereas expression levels were similar in the remaining 15%
of breasts (detailed data not shown). Proliferation was also
significantly elevated in HELUs as compared with TDLUs,
averaging 6.3 ± 0.47% and 2.0 ± 0.42%, respectively (P <
0.0001). In contrast, apoptosis was significantly lower in
HELUs than in TDLUs, averaging 0.22 ± 0.05% and 0.61 ±
0.05% (P < 0.0001). On average, only 4.9 ± 0.7% of prolifer-
ating normal epithelial cells in TDLUs simultaneously
expressed ER-α, compared with 27.6 ± 2.2% in HELUs,
which was also a highly significant difference (P < 0.0001).
Figure 3 shows representative photomicrographs of ER-α
expression, proliferation, and apoptosis in HELUs and TDLUs.
Changes in receptors and growth with menopausal 
status
Table 1 shows the relationships between ER-α expression, PR
expression, proliferation (Ki67), and apoptosis (TUNEL) in
TDLUs compared with HELUs in the same breasts stratified by
patient age as a surrogate for menopausal/estrogen status.
ER-α was significantly lower in TDLUs and HELUs in premen-
opausal than in postmenopausal breasts, with average propor-
tion scores of 2.65 versus 3.62 (approximately 25% versus
55%; P < 0.0001) and 4.37 versus 4.66 (approximately 75%
versus 90%; P = 0.013), respectively. PR was higher in pre-
menopausal than in postmenopausal TDLUs and HELUs, with
average proportion scores of 2.15 versus 2.01 (about 20%
versus 10%; P = 0.08) and 3.58 versus 3.34 (about 60% ver-
sus 45%; P = 0.02), respectively. The rates of proliferation
Figure 3
Examples of receptor expression and growth Examples of receptor expression and growth. This figure shows photomicrographs of representative examples of normal TDLUs and HELUs immu-
nostained for ER-α, the proliferation-associated marker Ki67, and apoptosis (as assessed using the TUNEL assay). In general, HELUs exhibited 
much higher levels of ER-α expression than did TDLUs. Expression of progesterone receptor was similar to that of ER-α (not shown). Proliferation 
was also significantly higher on average in HELUs than in TDLUs. In contrast, apoptotic rates were somewhat lower in HELUs than in TDLUs. The 
dark (black) nuclei are positive for ER-α, Ki67 (some circled), and apoptosis (some circled) in each panel. ER, estrogen receptor; HELU, hyperplastic 
enlarged lobular unit; TDLU, terminal duct lobular unit; TUNEL, terminal transferase-mediated dUTP nick end-labeling.Available online http://breast-cancer-research.com/content/8/1/R6
Page 5 of 9
(page number not for citation purposes)
were higher in premenopausal than in postmenopausal TDLUs
and HELUs, averaging 2.52% versus 1.38% (P = 0.024) and
7.32% versus 5.11% (P  = 0.017), respectively. Apoptosis
was significantly higher in TDLUs from premenopausal than
from postmenopausal breasts, averaging 0.80% and 0.43%
(P < 0.0001). In contrast, apoptosis was statistically similar in
premenopausal and postmenopausal HELUs (0.26% versus
0.18%; P = 0.38).
Discussion
Enlarged TDLUs, by any name, are a common alteration in the
adult female human breast. Although they have no well estab-
lished clinical significance, they have attracted considerable
attention recently, primarily because they may represent a very
early potential precursor of breast cancer – a suggestion that
dates as far back as the early 1900s [1-3]. The majority are
lined by a single layer of hyperplastic columnar epithelial cells
with minimal nuclear atypia, but a substantial minority exhibit
more diverse histologic features such as stratification of cells,
apocrine-like secretory features, and significant nuclear atypia,
contributing to the complex terminology that has evolved to
describe them [3,5,11-13].
More than 30 years ago, in one of the most enlightening
papers on this issue, Wellings and Jensen [9] described a '...
continuum of morphologic structures linking normal terminal
ductal lobular units ... to the entire group of dysplastic, meta-
plastic, hyperplastic, anaplastic, and neoplastic human mam-
mary lesions ...'. Enlarged TDLUs, which they referred to as
atypical lobules type A (and we refer to as HELUs), played a
central role in this continuum as an early 'hyperplastic' depar-
ture from normal TDLUs with the ability to develop or progress
into several other types of lesions in the breast, including atyp-
ical ductal hyperplasia (ADH). ADH is widely regarded as an
unequivocal but nonobligatory precursor of ductal carcinoma
in situ (DCIS), which in turn is considered to be a relatively
committed progenitor of invasive breast cancer (primarily the
so-called 'ductal' invasive breast cancers, which account for
about 80% of all invasive breast cancers). In this sense,
HELUs can be viewed as the earliest histologically identifiable
potential precursor of breast cancer. In Wellings' and Jensen's
words [9,23], '... atypical lobules type A ... showed variable
degrees of anaplasia forming [a] continuum from normal lob-
ules to ductal carcinoma in situ ...'.
The Wellings and Jensen model was based almost entirely on
the evidence of gradual histologic continuity observed
between thousands of samples of normal and abnormal
human breast tissues examined grossly and microscopically,
and it was consistent with previous observations in mouse
models of breast cancer that they later extended to humans
[9]. We have confirmed these observations and found the
model to be very compelling, with minor modifications of our
own (Figs 4 and 5). Gradual histologic continuity of this mag-
nitude is persuasive evidence and is as close as possible to
observing tumor progression in humans. In addition, the model
has withstood the test of time in the sense that it remains con-
sistent with newer discoveries such as the escalating risk for
developing breast cancer associated with HELUs (about two-
fold), ADH (about fivefold), and DCIS (about 10-fold) [5,6,24-
29], and the shared genetic alterations between them, espe-
cially when they occur in the same breasts [30-34].
In our view, progression in this model is probably very slow
overall and nonobligatory so, for example, only a small subset
of HELUs may ever progress to ADH or beyond. Whether and
how progression proceeds is probably dictated by the accu-
mulation of specific genetic and epigenetic abnormalities in a
largely random manner. We doubt that the artificially defined
sequential stages in this morphologic model represent the only
Table 1
Changes in receptors and growth with menopausal status
Marker Age ≤50 years (mean ± SEM) Age >50 years (mean ± SEM) P value
ER-α-TDLUa 2.65 ± 0.06 (n = 342) 3.62 ± 0.06 (n = 273) <0.0001
ER-α-HELUa 4.37 ± 0.07 (n = 201) 4.66 ± 0.07 (n = 197) 0.013
PR-TDLUa 2.15 ± 0.09 (n = 383) 2.01 ± 0.10 (n = 264) 0.08
PR-HELUa 3.58 ± 0.10 (n = 274) 3.34 ± 0.10 (n = 236) 0.02
Ki67-TDLU 2.52 ± 0.67 (n = 106) 1.38 ± 0.69 (n = 95) 0.024
Ki67-HELU 7.32 ± 0.74 (n = 67) 5.11 ± 0.73 (n = 69) 0.017
TUNEL-TDLU 0.80 ± 0.06% (n = 234) 0.43 ± 0.07% (n = 142) <0.0001
TUNEL-HELU 0.26 ± 0.06% (n = 215) 0.18 ± 0.07% (n = 140) 0.38
This table compares average ER-α expression, PR expression, proliferation rate (Ki67), and apoptosis rate (TUNEL) between normal TDLUs and 
HELUs from the same breasts, stratified by age as a surrogate for menopausal/estrogen status. aAverage proportion score representing the 
estimated proportion of positive cells (0 = none, 1 < 1/100, 2 = 1/100 to 1/10, 3 = 1/10 to 1/3, 4 = 1/3 to 2/3, and 5 = >2/3). ER, estrogen 
receptor; HELU, hyperplastic enlarged lobular unit; TDLU, terminal duct lobular unit; PR, progesterone receptor; TUNEL, terminal transferase-
mediated dUTP nick end-labeling.Breast Cancer Research    Vol 8 No 1    Lee et al.
Page 6 of 9
(page number not for citation purposes)
pathway to breast cancer, but it is probably a very important
one because the histologic continuity is so strong, in addition
to the epidemiologic and genetic evidence already mentioned.
There are many other types of benign proliferative lesions in
the breast that, for the most part, do not exhibit substantial his-
tologic continuity with breast cancer; therefore, if other path-
ways to cancer exist, then they must be histologically subtle,
perhaps occurring at the level of individual cells or too rapidly
to be easily observed.
The growth and differentiation of normal breast epithelial cells
lining TDLUs are regulated by many biologic mechanisms,
especially one involving circulating estrogen, which binds and
activates the nuclear transcription factor ER-α [16,35]. Among
many functions, activated ER-α regulates the synthesis of PR,
another nuclear transcription factor that, in response to pro-
gesterone, also helps to regulate growth and differentiation in
normal cells [16,35,36]. The present study evaluated and con-
trasted ER-α, PR, and growth (proliferation and apoptosis) in
TDLUs and adjacent HELUs to gain insight into the relative
loss of growth control (i.e. hyperplasia) leading to develop-
ment of the latter.
Consistent with earlier studies [33], we observed that nearly
all TDLUs contained ER-α-positive cells, averaging about
35%. Using age as a surrogate for menopausal and estrogen
status, expression in TDLUs was significantly lower in premen-
opausal than in postmenopausal breasts, which has previously
been reported [33] and which is consistent with the normal
negative regulation of ER-α by estrogen [16]. In contrast,
about 85% of cells in HELUs expressed ER-α; this is much
higher than in TDLUs and is consistent with another recent
report of elevated ER-α in HELUs [34]. Similar to TDLUs, ER-
α expression in HELUs was significantly lower in premenopau-
sal than in postmenopausal breasts, suggesting that hyper-
plastic cells remain responsive to regulation by estrogen,
although to a lesser degree than normal cells do. It will be
important to determine the fundamental causes for the large
elevation in ER-α in HELUs. Overall, the findings for PR were
similar to those for ER-α, with the exception that PR levels
were relatively higher in premenopausal samples, which is
Figure 4
Modified Wellings Jensen model of breast cancer evolution Modified Wellings Jensen model of breast cancer evolution. This figure illustrates our interpretation of the model of 'ductal' breast cancer evolution 
originally proposed by Wellings and Jensen [9], which was based almost entirely on the evidence of histologic continuity. In this model, hyperplastic 
breast epithelial cells gradually enlarge normal TDLUs to form HELUs. HELUs may then differentiate to microcysts (often with apocrine features) or 
progress to more complex lesions including UDH and ADH. ADH may progress to DCIS as the cells continue to proliferate and distend the acini, 
and DCIS may eventually progress to IBC. Progression is probably very slow overall and nonobligatory, so, for example, only a small subset of 
HELUs ever progress to ADH or beyond. Whether and how differentiation and progression proceed is probably dictated by the acquisition of spe-
cific genetic and epigenetic abnormalities in a largely random manner. ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; HELU, 
hyperplastic enlarged lobular unit; IBC, invasive breast cancer; TDLU, terminal duct lobular unit; UDH, usual ductal hyperplasia.Available online http://breast-cancer-research.com/content/8/1/R6
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consistent with normal induction of PR by estrogen-activated
ER-α [16,36].
Estrogen and progesterone are potent growth factors for nor-
mal breast epithelium [15,16,35,36], which is consistent with
our observation that average proliferation was significantly
higher in TDLUs from premenopausal than in postmenopausal
breasts, which has also been observed by others [33,35]. A
reasonable hypothesis for the development and growth of
HELUs is increased proliferation due to large increases in ER-
α and PR, which are the receptors for these mitogens. Con-
sistent with this, we observed a significant (more than three-
fold) increase in average proliferation in HELUs compared with
adjacent TDLUs. A recent study [37] which transfected and
over-expressed murine ER-α in the epithelium of mouse mam-
mary glands noted the rapid development of hyperplasias,
which occasionally progressed to DCIS; this supports the
notion that elevated ER-α may be partially responsible for the
development of HELUs and their progression to more
advanced lesions in humans. However, a substantial (about
15%) subset of HELUs did not exhibit elevated ER-α, suggest-
ing that other mechanisms may also be involved.
In our study, the range of proliferation rates in HELUs was
wide (0–36%), exhibited significant overlap with TDLUs, and
was somewhat bimodal. Proliferation at the low end of this
bimodal distribution averaged only about 2% (similar to
TDLUs) but was about 15% at the high end (far above
TDLUs), and perhaps a subset of the latter group of HELUs is
more likely to progress to lesions with higher breast cancer
risk such as ADH.
In normal breast, proliferating cells are almost always (>95%)
ER-α negative; conversely, ER-α positive cells are rarely
(<5%) proliferating [35,38,39]. It is currently unknown
whether this reflects separate populations of stable cells or the
same population in which receptor expression and
proliferation vary with time (e.g. during the cell cycle). Because
hormones (especially estrogen) are required for proliferation,
the latter hypothesis is plausible, but the former could be
explained by paracrine signaling between stable ER-α-positive
cells promoting proliferation in nearby stable ER-α-negative
cells, and these possibilities are not mutually exclusive
[15,35]. Regardless, estrogen is necessary to stimulate prolif-
eration in normal cells. Compared with TDLUs, HELUs
exhibited a more than fivefold increase in the average percent-
age of ER-α-positive proliferating cells (4.9% versus 27.6%
overall), suggesting that the hormonal regulation of prolifera-
tion in these cells is altered and/or that other pathways have
been activated that stimulate proliferation independent of ER-
Figure 5
Stages of breast cancer evolution Stages of breast cancer evolution. This figure shows representative photomicrographs of important artificially defined stages of the Wellings–Jensen 
model of 'ductal' breast cancer evolution, including normal TDLUs, HELUs, ADH, DCIS, and IBC. ADH, atypical ductal hyperplasia; DCIS, ductal 
carcinoma in situ; HELU, hyperplastic enlarged lobular unit; IBC, invasive breast cancer; TDLU, terminal duct lobular unit.Breast Cancer Research    Vol 8 No 1    Lee et al.
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α expression. A similar increase in ER-α-positive proliferating
cells has previously been reported in more advanced precur-
sors (e.g. ADH and DCIS) and invasive breast cancer
[35,38,39], which is consistent with the hypothesis that
HELUs represent an earlier stage of the same continuum.
In mice, as in humans, ER-α-positive/proliferating normal epi-
thelial cells are relatively rare, and a recent study in mice [40]
suggested that they may represent important mammary pro-
genitor cells in which proliferation is inhibited by autocrine sig-
naling through transforming growth factor (TGF)-β1, resulting
in a normally large population of ER-α-positive/nonproliferating
cells. The study further showed that when TGF-β1 signaling is
inhibited, the proportion of ER-α-positive/proliferating cells
increases dramatically, reaching the levels we observed in
HELUs. Therefore, HELUs perhaps represent an expanding
population of precursor cells resulting from delayed differenti-
ation associated with decreased TGF-β1 signaling, and it will
be important to assess the status of TGF-β1 in HELUs.
The rate of cell death also contributes to the overall growth of
cellular tissues. We observed a relatively low average rate of
apoptosis in normal TDLUs (about 0.61%), which was signifi-
cantly higher (about twofold) in premenopausal than postmen-
opausal breasts, which is consistent with normal estrogen
regulation of programmed cell death in the breast [41]. In con-
trast, apoptosis was significantly lower in HELUs (about
0.22%), and it did not fluctuate significantly with menopausal
status, suggesting that estrogen regulation of apoptosis may
be abnormal.
Conclusion
HELUs are a common alteration of normal TDLUs and repre-
sent the earliest histologically identifiable potential precursor
of breast cancer. The prominent hyperplasia leading to the
development of HELUs is associated with both increased pro-
liferation and decreased cell death relative to normal cells. ER-
α and PR are highly elevated in HELUs, which may partially
explain this hyperplasia because they are the receptors for the
hormones that regulate proliferation and apoptosis, although
additional mechanisms are likely to be involved. Future studies
will hopefully reveal the fundamental causes of increased
receptor expression and growth in HELUs, which may lead to
better prediction of breast cancer risk and new strategies for
preventive therapy.
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